Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

NCT02289716 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis
Pain

Interventions

DRUG: Placebo
DRUG: Fulranumab 1 mg
DRUG: Fulranumab 3 mg

Sponsor

Janssen Research & Development, LLC